POLN

DNA polymerase nu · Q7Z5Q5 · POLN on Sugi Atlas →

29 patent compounds predicted against POLN, 3 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL29412063 SCHEMBL29412063 0.69 3/20
SCHEMBL29664093 SCHEMBL29664093 0.51 2/20
SCHEMBL31536868 SCHEMBL31536868 0.48 2/20

Clinical trials — most relevant to POLN by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection PHASE3UNKNOWN
Intracameral Antibiotic Safety Study PHASE3SUSPENDED
A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve) PHASE3WITHDRAWN
Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD) PHASE3COMPLETED
Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer PHASE2UNKNOWN
Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer PHASE2COMPLETED
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations PHASE1/PHASE2COMPLETED
Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL) PHASE2RECRUITING
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability PHASE2ACTIVE_NOT_RECRUITING
Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations PHASE2COMPLETED
Olaparib in People With Malignant Mesothelioma PHASE2COMPLETED
Selective Treatment According to Molecular Subtype of Prostate Cancer PHASE2UNKNOWN
Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial) PHASE2UNKNOWN
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors PHASE1COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas PHASE1COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors PHASE1COMPLETED
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors PHASE1ACTIVE_NOT_RECRUITING
Pre-Operative Radiation and Veliparib for Breast Cancer PHASE1COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors PHASE1COMPLETED
Prevalence of Germline Alterations in Actionable Genes in Endometrial Cancer nanNOT_YET_RECRUITING
Choroid Plexus Dysfunction in Neurological Diseases nanRECRUITING
Cohort of Tumors With POLE/D1 Mutation nanRECRUITING
North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) nanRECRUITING
Natural History in Primary Mitochondrial Myopathies nanRECRUITING
Chronic Cough and CANVAS (Cerebellar Ataxia With Neuropathy and Bilateral Vestibular Areflexia Syndrome) nanCOMPLETED
DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease nanCOMPLETED
Plant Extracted Natural Compounds Impact on Stage IV Breast Cancer Survival Time and Remission. nanUNKNOWN
REal Word aPpLicAtion of Molecular Based Endometrial Cancer Classification nanRECRUITING
The Impact of Myomectomy on IVF Outcomes nanNOT_YET_RECRUITING
Ccf mtDNA as a Neurodegenerative Biomarker nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a POLN binder may also engage these)

ProteinNameSimilarity
Q7TQ07 1.000 Q7TQ07 →
Q9CZB3 0.973 Q9CZB3 →
Q60953 0.973 Q60953 →
Q6R3M4 0.973 Q6R3M4 →
D2H3M0 0.971 D2H3M0 →
D2H8V8 0.971 D2H8V8 →
Q5F3V0 0.970 Q5F3V0 →
Q9BVS5 0.969 Q9BVS5 →
A9Z1V5 0.969 A9Z1V5 →
A4D0V7 0.968 A4D0V7 →
Q8C1F5 0.968 Q8C1F5 →
D2HNY3 0.967 D2HNY3 →
A0JPF9 0.967 A0JPF9 →
Q8NHP7 0.967 Q8NHP7 →
Q96AY2 0.967 Q96AY2 →
Q5TIE3 0.966 Q5TIE3 →
E1BPH3 0.966 E1BPH3 →
Q8C0V1 0.966 Q8C0V1 →
Q501R9 0.966 Q501R9 →
Q3US16 0.966 Q3US16 →
Q9Y2M0 0.966 Q9Y2M0 →
Q9QYV8 0.965 Q9QYV8 →
Q5M7P8 0.965 Q5M7P8 →
Q8TAM1 0.965 Q8TAM1 →
Q1L981 0.965 Q1L981 →
Q8NAT2 0.965 Q8NAT2 →
Q7TT79 0.964 Q7TT79 →
Q7TPQ3 0.964 Q7TPQ3 →
Q8WTP8 0.964 Q8WTP8 →
Q5VCS6 0.964 Q5VCS6 →